SCHEMBL3536101

SCHEMBL3536101

CNc1ccc([N+](=O)[O-])c(N2CCCCC2)c1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.64
MAPT P10636 12/20 0.63
CYP1A2 P05177 3/20 0.63
CYP2C19 P33261 3/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
LMNA P02545 3/20 0.61
POLB P06746 3/20 0.61
HPGD P15428 2/20 0.59
CYP2C9 P11712 2/20 0.59
KMT2A Q03164 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
NPSR1 Q6W5P4 1/20 0.57
MAPK1 P28482 4/20 0.56
GAA P10253 2/20 0.54
ALDH1A3 P47895 1/20 0.51
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041156 0.87 ALDH1A1 (0.63) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1
SCHEMBL7805753 0.83 MAPT (0.62) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1
SCHEMBL5098076 0.83 MAPT (0.62) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1
SCHEMBL25891601 0.81 ALDH1A1 (0.68) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1
SCHEMBL7808036 0.81 MAPT (0.64) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1
SCHEMBL22094933 0.80 MAPT (0.97) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1
SCHEMBL8794400 0.80 ALDH1A1 (0.69) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1
SCHEMBL3536564 0.80 MAPT (0.97) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1
SCHEMBL14900317 0.79 MAPT (0.62) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1
SCHEMBL7045400 0.79 ALDH1A1 (0.53) ALDH1A1MAPTCYP1A2CYP2C19L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
US-7427683-B2 c-fms kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-09-23 US disclosed
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131022-A1 C-fms kinase inhibitors FLT3, FES, FGR ALDH1A1 4568/4885MAPT 296/4885CYP1A2 3681/4885
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES ALDH1A1 4796/4885MAPT 159/4885CYP1A2 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.